bg-img9.jpg
8.jpg
Cell Therapy Manufacturing & Gene Therapy Congress

We are pleased to announce our participation as a sponsor at the upcoming Cell Therapy Manufacturing & Gene Therapy Congress in Amsterdam. The event will focus on connecting cell and gene therapy leads to drive manufacturing and commercialization through direct access to innovative discovery, product development and regulatory know-how. We are honored to showcase our global integrated solution for cell therapy clinical and commercial development in conjunction with our parent company, Thermo Fisher Scientific.

Topic: Cell Therapy Solutions, Content: Blog

Creation of the First Tuberculosis Biobank in the UK

After the discovery of Streptomycin in the 1940s, followed by isoniazid in the 1950s and later rifampin in the 1970s, the incidence of Tuberculosis (TB) in the developed world dropped dramatically. Sanatoria closed and research into new antibiotics and vaccines likewise diminished. TB was no longer considered a significant threat in the US and much of Europe. So when multiple drug-resistant strains of TB (MDR-TB) appeared in the 1980s, the concern within the infectious disease community was perhaps understated. Besides, all but a small number of cases were in underdeveloped countries where the very high cost and difficulty of treating MDR-TB was considered beyond reach.

Topic: Biobanking and Biorepository, Content: Post..........

European Biobank Week: Biobanking for health innovation

Biobanks serve a common goal: to improve understanding of patients, diseases and health; and to deliver the best individualized care. Sample quality is paramount to achieving that goal. Without confidence in the integrity of biosamples, there can be no confidence in the results.  To support this effort, we are pleased to announce our participation at the upcoming European Biobank Week (EBW) in Vienna, Austria.

Topic: Biobanking and Biorepository, Content: Blog

[Video] Semi-Automated Biobanking: Delivering quality samples in less time

The holy grail in the biobanking industry is all about maximizing the value of biospecimens to deliver new therapies. Thus, there's now more pressure on biobanks to deliver samples that are in better condition, with better annotation, and with a more rapid turnaround time. In order to support our clients in achieving their aims in maximizing the value of their sample collections, we have installed a LiCONiC Semi-Automated Biobank (SAB) to manage the increased demands on sample utilization. To learn more and see the LiCONiC system in action, check out our video below!

Content: Video, Topic: Biobanking and Biorepositor..........

Safeguarding Data Across Biotech Global Boundaries

In an era of “big data,” companies across all industries are collecting consumer information to provide effective solutions to problems or better market their products. Industry watchdog groups have long been concerned about the implications of data collection on consumer privacy. These issues become even more complex when conducting transactions across international borders. A recently drafted European Union-United States Privacy Shield agreement is intended to clarify the privacy principles U.S. organizations must meet to comply with EU privacy laws.

Topic: Biobanking and Biorepository, Content: Blog

World Stem Cells & Regenerative Medicine Congress


We are pleased to announce our participation at the 11th Annual World Stem Cells & Regenerative Medicine Congress on May 18-20 in London, England. In the past, this event focused on developments in stem cell therapies and innovations within regenerative medicine. As the industry progresses, this year's conference will focus on the cell therapies that have made it to market, the innovations of academia and universities, and the use of stem cells for drug discovery. Additionally, this year's event will be co-located with World Precision Medicine Congress and the Cord Blood World Europe.

Topic: Biobanking and Biorepository, Topic: Cell T..........

Managing the Cold Chain to Minimize Pre-Analytical Variability: ISBER 2015 Flashback

The value of your work lies in the integrity of your specimens. Ensuring samples are maintained at the proper temperature throughout all processes is imperative to maximal long term viability and usability. This means not only during the processing and preparation of samples for analysis or storage—it also means during the transportation process. Moving samples between physical locations is a necessary part of biobanking, whether the locations are separated by a lab, a building or even a continent.

With ISBER 2016 right around the corner, let's take a trip down memory lane and review last year's workshop, presented by Alex Esmon PhD, global cold storage product manager at Thermo Fisher Scientific, on the importance of maintaining the cold chain during sample transport.

Topic: Biobanking and Biorepository, Content: Blog

EU Commission Guidelines on Good Distribution Practice of IMP

Over the past few years there has been a notable increase in the number of temperature-controlled clinical supplies being transported all over the world. This increase can be attributed to the fact that a larger number of clinical trial drugs being tested today are of a biological nature. However, as discussed on the Fisher Clinical Services INSIGHTS blog, until recently little thought was given to ambient drug (generally set to be stored within 15°C – 25°C) being transported through a temperature controlled method as well.

Topic: Cold-Chain Logistics, Topic: GMP Biologics ..........

A Paradigm Shift in Biobanking: The Future of Cell Preservation Strategies

Once considered “old school,” cryopreservation is going through another scientific and technological development growth phase. Today’s new cryopreservation processes and products promise to deliver disruptive technologies to discovery science, stem cell research, diagnostics and personalized medicine; forever changing the future of cell preservation strategies.

Cell preservation has evolved from simple, often poorly annotated private collections of clinical specimens to highly organized and well-annotated collections maintained by commercial and not-for-profit organizations. Currently, the focus of cell preservation strategies is from government and international agencies on the activities of biobanks, specifically on the need to adopt best practices and to provide scientific, legal and ethical guidelines for the biopreservation industry. Cell preservationists still focus on fulfilling the immediate post-thaw viability needs of today’s researchers.

Topic: Biobanking and Biorepository, Topic: Cell T..........